4.3 Site Initiation Preparation, System Access & Regulatory Greenlight

Site Initiation Preparation, System Access & Regulatory Greenlight

Exam scope note: This section cites national regulations (for example US Code of Federal Regulations provisions) because they shape day-to-day practice. ACRP states the ACRP-CP exam is referenced only to ICH Guidelines and that no country-specific framework is tested. Treat those citations as professional context; the provision examined here is ICH E6(R3) Annex 1 sections 1.4.6 (no enrolment before documented IRB/IEC approval), 2.2 (Resources) and 3.8 (Communication with IRB/IEC and Regulatory Authorities).

Core Requirement: Under ICH E6(R3) Annex 1 section 3.15.3 and 21 CFR 312.60, a sponsor must not supply an investigational product (IP) to an investigative site until the sponsor has obtained all required regulatory documentation, formal Institutional Review Board (IRB) approval, a fully executed contract, and verified that site personnel are thoroughly trained on the protocol. The formal process through which these conditions are verified and approved is termed the Regulatory Greenlight (or IP Release Authorization).

The period between site selection and the enrollment of the First Patient In (FPI) is the Start-Up Execution Phase. Candidates preparing for the ACRP-CP examination must understand the critical path of the regulatory greenlight checklist, the conduct of the Site Initiation Visit (SIV), and the strict electronic system provisioning requirements governed by 21 CFR Part 11.

---

1. The Regulatory Greenlight: IP Release Checklist

The Regulatory Greenlight is a rigorous quality control checkpoint managed by the sponsor's Regulatory Operations or Quality Assurance (QA) department. No investigational product can be shipped, and no subject can be screened, until every item in the greenlight package is verified and approved.

┌───────────────────────────────────────────────────────────────────────────┐
│                     REGULATORY GREENLIGHT PACKET CHECKLIST                │
├───────────────────────────────────────────────────────────────────────────┤
│  1. Fully Executed Clinical Trial Agreement (FTE CTA) & Final Budget      │
│  2. Unconditional IRB/IEC Approval Letter (Protocol & Site Approval)     │
│  3. IRB-Approved Informed Consent Form (ICF) with valid version/date      │
│  4. Form FDA 1572 (Signed & dated by PI, listing all sub-Is & facilities) │
│  5. 21 CFR Part 54 Financial Disclosure Forms (PI & all Sub-Is on 1572)   │
│  6. Current Curriculum Vitae (Signed/dated ≤2 yrs) & Active Medical License│
│  7. GCP & Human Subject Protection Training Certifications for all staff  │
│  8. Local Clinical Laboratory Certification (CLIA/CAP) & Normal Ranges    │
│  9. Signed Protocol Signature Page & Investigator's Brochure Ack.         │
│ 10. Completed & PI-Signed Delegation of Authority Log (DOAL)              │
│ 11. Completed Site Initiation Visit (SIV) & Signed Training Log           │
│ 12. Validated Electronic Systems Provisioning (EDC / IRT / eCOA)          │
└───────────────────────────────────────────────────────────────────────────┘

Detailed Analysis of Essential Greenlight Documents

---

2. The Site Initiation Visit (SIV)

The Site Initiation Visit (SIV) is conducted after the site has secured IRB approval and contracts, either immediately prior to or concurrent with final regulatory greenlight. The SIV is conducted by the Clinical Research Associate (CRA/Monitor) or study team leadership to train the site on the operational execution of the protocol.

┌───────────────────────────────────────────────────────────────────────────┐
│                        MANDATORY SIV AGENDA TOPICS                        │
├───────────────────────────────────────────────────────────────────────────┤
│  • Detailed Protocol Review: Study objectives, endpoints & visit schedule  │
│  • Eligibility Criteria: Strict review of inclusion/exclusion parameters  │
│  • Informed Consent Procedures: Step-by-step consent & re-consent rules   │
│  • Safety Reporting: Serious Adverse Event (SAE) 24-hour reporting rules  │
│  • Investigational Product: Receipt, storage, temperature logs & dosing   │
│  • Laboratory Procedures: Blood collection, processing, PK handling, IATA │
│  • Electronic Data Capture (EDC): eCRF completion guidelines & queries   │
│  • Interactive Response Technology (IRT): Randomization & kit allocation  │
│  • Trial Monitoring Logistics: Frequency of IMVs, SDV scope & space       │
└───────────────────────────────────────────────────────────────────────────┘

Mandatory Attendees at the SIV

• Principal Investigator (PI): Must attend the meeting and participate in protocol discussions to fulfill supervisory obligations.
• Sub-Investigators: All participating co-investigators who will perform medical evaluations, consent subjects, or evaluate safety.
• Clinical Research Coordinators (CRCs) & Research Nurses: The primary operational leads for subject visits and data management.
• Investigational Pharmacist: Must review drug accountability, storage, reconstitution, and blinding procedures.
• Laboratory Coordinator / Processing Tech: Must review blood tube centrifugation, -80°C storage, and dry ice shipping.

Exam Watchout: If a key team member (e.g., the research pharmacist or primary coordinator) is absent from the SIV, they cannot perform protocol-specific tasks until they receive documented protocol training and sign the training log.

---

3. Electronic System Access & User Provisioning (21 CFR Part 11)

Modern clinical trials depend on a multi-system software ecosystem. Access to these systems must comply with 21 CFR Part 11 (Electronic Records; Electronic Signatures) and ICH E6(R3) Annex 1 section 4.3.

┌───────────────────────────────────────────────────────────────────────────┐
│                     CLINICAL TRIAL ELECTRONIC ECOSYSTEM                   │
├───────────────────────────────────────────────────────────────────────────┤
│  1. Interactive Response Technology (IRT / RTSM)                          │
│     • Real-time randomization, stratifications & IP kit dispense tracking │
├───────────────────────────────────────────────────────────────────────────┤
│  2. Electronic Data Capture (EDC)                                         │
│     • eCRF data entry, electronic queries, PI electronic signatures        │
├───────────────────────────────────────────────────────────────────────────┤
│  3. Electronic Clinical Outcome Assessment (eCOA / ePRO)                  │
│     • Participant electronic diaries, symptom scales, clinic tablet entry │
├───────────────────────────────────────────────────────────────────────────┤
│  4. Electronic Investigator Site File (eISF / eRegulatory)                │
│     • Digital repository for essential regulatory documents & DOAL       │
└───────────────────────────────────────────────────────────────────────────┘

Principles of Compliant Electronic User Provisioning

1. Role-Based Access Control (RBAC): Users are granted access strictly according to their delegated roles on the DOAL (e.g., a data entry CRC cannot execute the PI electronic signature on eCRFs; a blinded coordinator cannot view unblinded pharmacy kit assignment screens in the IRT).
2. Individual, Non-Shared Credentials: Every user must have unique login credentials (username and password/MFA). Sharing passwords or entering data under another user's profile is a severe 21 CFR Part 11 violation.
3. Prerequisite Training Verification: System administrators will not issue active system credentials until documented completion of system-specific training modules is verified.
4. Audit Trail Integrity: All electronic systems must maintain an automated, computer-generated, time-stamped audit trail capturing the identity of the user, date/time, original value, new value, and reason for change for every data entry or modification.

---

4. Pharmacy Dispensing Readiness & Investigational Product Release

Before the first dose of investigational product can be dispensed to a trial participant, the investigative pharmacy must achieve full operational readiness.

┌───────────────────────────────────────────────────────────────────────────┐
│                    PHARMACY OPERATIONAL READINESS GATES                   │
├───────────────────────────────────────────────────────────────────────────┤
│  1. Storage Condition Validation                                          │
│     • Continuous, calibrated temperature data loggers operational         │
│     • Refrigerator (2°C–8°C) / Freezer (-20°C / -80°C) mapping complete   │
├───────────────────────────────────────────────────────────────────────────┤
│  2. Drug Receipt & Accountability Documentation                           │
│     • Formal inspection of IP shipment: verify tamper seals, quantity,    │
│       lot numbers, and transit temperature monitor (TempTale) status      │
│     • Acknowledge receipt in IRT system to release kits into active stock │
├───────────────────────────────────────────────────────────────────────────┤
│  3. Preparation & Compounding Protocols                                   │
│     • Pharmacy Manual on file detailing reconstitution, diluent types,    │
│       filtration, infusion bag compatibility, and hold-time stability     │
│     • Sterile compounding compliance (USP <797>) and hazardous (USP <800>)│
├───────────────────────────────────────────────────────────────────────────┤
│  4. Blinding & Code-Break Safeguards                                      │
│     • Unblinded pharmacy staff designated if study drug requires unblinded│
│       preparation (e.g., masking colored solutions or custom packaging)   │
│     • Emergency 24/7 unblinding instructions verified in IRT              │
└───────────────────────────────────────────────────────────────────────────┘

Investigational Drug Accountability Logs

Under 21 CFR 312.62(a) and ICH E6(R3) Annex 1 2.10, the investigator must maintain complete and accurate records of IP delivery to the site, inventory at the site, use by each subject, and return/destruction. The accountability record must capture:

• Date and quantity received from sponsor.
• Batch / lot / kit identification number.
• Expiration or re-test date.
• Subject ID and visit number to whom IP was dispensed.
• Quantity dispensed, date dispensed, and initials of dispensing pharmacist/investigator.
• Quantity returned by subject, empty vials/bottles reconciled, and date returned.
• Discrepancies and formal investigation notes.

---

Realistic Clinical Scenario: Greenlight Deficiency and Delayed Activation

Scenario: A clinical trial site is preparing for site initiation on a multi-center Phase II oncology study. The CRA conducts the SIV on Tuesday. On Wednesday, the site receives an eligible, newly diagnosed patient who requires immediate therapy initiation on Thursday. The CRC rushes to enroll the subject, access the IRT system to randomize the patient, and request that the pharmacy dispense the investigational drug.

Upon review, the sponsor's Regulatory Operations manager discovers the following:

1. The local laboratory reference ranges submitted were signed by the lab supervisor, but the Lab Director's CV was missing from the essential document packet.
2. The newly hired Sub-Investigator who performed the patient's baseline physical exam and eligibility confirmation on Wednesday morning signed the protocol training log at the SIV, but the PI has not yet signed the updated Delegation of Authority Log (DOAL) adding the Sub-Investigator.
3. The formal Sponsor Greenlight Authorization letter has not been issued.

Regulatory & Operational Determination:

• Prohibition of Randomization: The site is in Greenlight Hold. The site cannot randomize the patient, and the pharmacy cannot dispense investigational product.
• Corrective Actions Required:
  • The site must obtain the Lab Director's signed CV and submit it to the sponsor.
  • The PI must review, sign, and date the DOAL formally delegating clinical trial duties to the new Sub-Investigator.
  • The PI must re-verify the baseline physical exam or perform the medical eligibility evaluation personally.
  • The sponsor Regulatory Operations department must verify all items and formally issue the written Regulatory Greenlight.
• Consequence of Premature Dosing: If the site had dispensed the drug prior to formal greenlight and prior to PI DOAL sign-off, it would constitute a major protocol violation and an unauthorized drug administration finding under FDA inspection.